Raiffeisen Bank International’s Neurocrine Biosciences NBIX Stock Holding History

Raiffeisen Bank International’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Buy	13,864 +1,364	+11%	+$202K	0.03%	279
2026 Q1	$1.61M	Sell	12,500 -6,100	-33%	-$809K	0.02%	339
2025 Q4	$2.62M	Buy	18,600 +533	+3%	+$77.2K	0.03%	229
2025 Q3	$2.53M	Buy	18,067 +1,258	+7%	+$170K	0.03%	217
2025 Q2	$2.15M	Buy	16,809 +551	+3%	+$63.2K	0.03%	215
2025 Q1	$1.84M	Buy	16,258 +4,858	+43%	+$615K	0.03%	222
2024 Q4	$1.56M	Buy	+11,400	New	+$1.41M	0.02%	235

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Raiffeisen Bank International's NBIX Position: Q2 2026 in Review

Raiffeisen Bank International increased its Neurocrine Biosciences (NBIX) stake by 11% in Q2 2026, buying an estimated $202K and bringing the position to 13,864 shares worth $2.36M. The position accounts for 0.03% of the portfolio, ranked #279.

Raiffeisen Bank International first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.62M in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Raiffeisen Bank International held 13,864 shares of Neurocrine Biosciences worth $2.36M as of Q2 2026.
Raiffeisen Bank International bought 1,364 Neurocrine Biosciences shares in Q2 2026, an estimated $202K.
Neurocrine Biosciences made up 0.03% of Raiffeisen Bank International's portfolio in Q2 2026, its #279 holding.
Raiffeisen Bank International first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
Raiffeisen Bank International's Neurocrine Biosciences position peaked at $2.62M in Q4 2025.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Raiffeisen Bank International's 13F filing for Q2 2026, filed 3 Aug 2026.